Recruiting × Carcinoma, Hepatocellular × Genitourinary × Clear all PSI-Immune
Phase 2 Recruiting
880 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
595 enrolled
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Phase 1 Recruiting
70 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Phase 1/2 Recruiting
170 enrolled
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Recruiting
300 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
ELEPHAS-04
Recruiting
324 enrolled
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Recruiting
500 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
IMPACT
Phase 1 Recruiting
21 enrolled
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2 Recruiting
520 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 Recruiting
27 enrolled
ODYSSEY
Phase 4 Recruiting
2,076 enrolled
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Phase 1 Recruiting
43 enrolled
CCANED-CIPHER
Recruiting
6,000 enrolled
ELEPHAS-02
Recruiting
416 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
A Study of DEG6498 in Participants With Solid Tumors
Phase 1 Recruiting
100 enrolled
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 Recruiting
50 enrolled
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 Recruiting
10 enrolled
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
862 enrolled
Indocyanine Green (ICG) Guided Tumor Resection
Phase 1 Recruiting
230 enrolled
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Phase 1 Recruiting
21 enrolled
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting
50,000 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/2 Recruiting
40 enrolled
MOIO
Phase 3 Recruiting
646 enrolled
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Phase 1 Recruiting
24 enrolled
A Multicenter Cancer Biospecimen Collection Study
Recruiting
1,650 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Phase 2/3 Recruiting
200 enrolled